Duramed/Schein conjugated estrogens settlement
Schein has given up claims to any rights over Duramed's Cenestin (conjugated estrogens A) product. Duramed has paid Schein $7.5 mil. as part of the settlement, and an additional $7.5 mil. in cash or stock is due Jan. 20. If Cenestin sales exceed $100 mil. over any five year period in the next 15 years, Schein is entitled to another $15 mil
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth